Key facts
- NodThera’s last known valuation is $151.8M (May 2020).
- It has raised $151.9M; the latest was Later Stage VC ($49.8M) in Apr 2025.
- Notable investors include F-Prime Capital, Eight Roads, Novo Holdings, Sofinnova Partners, Blue Owl Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for NodThera
- ·The full record, as it builds
Funding rounds
No funding rounds for NodThera are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NodThera
Operator of a biotechnology company intended to develop medicines to treat diseases driven by chronic inflammation. The company's drug development portfolio includes a pipeline of potent and selective inflammasome inhibitors used to reduce pro-inflammatory cytokines which are known to play a key role in chronic inflammation, enabling medical practitioners to effectively treat patients with many chronic diseases.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2016
- Employees
- 24
- Website
- nodthera.com/
- Ownership
- Privately Held (backing)
NodThera doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NodThera shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NodThera in its N-PORT filings yet. We sweep new filings monthly.